Prof. Dr. rer. nat. habil. Udo S. Gaipl is Head of Translational Radiobiology and Group Leader of Radiation Immunobiology at Universitätsklinikum Erlangen (UKER) at the Department of Radiation Oncology. In 2003, he obtained his Dr. rer. nat. with ward and following a PostDoc time (2003-2005) at the Hospitale San Raffaele in Milano at the tumor immunology unit, he returned to Erlangen as group leader and continued his work on stressed cells as a tool for immune intervention. In 2007, he founded the Radiation Immunobiology at UKER and since 2020 he is head of Translational Radiobiology. Prof. Gaipl is further member of the board of directors of the German Society for Radiation Oncology (DEGRO) and 1st Chairman of the German Society for Biological Radiation Research (DeGBS) and Board Member of the European Society for Hyperthermic Oncology (ESHO). Since 2015 he is Professor for Experimental Medicine and has published about 240 peer-reviewed papers on immune modulations by radiation and by activated and stressed cells. His papers are highly cited (h-index: 52) and his group significantly contributed to the paradigm shift that not only targeted effects of radiation on the DNA do exist, but also systemic and immune-mediated ones. His research focuses on immune modulation by activated, stressed and dying tumor cells, on radiation-induced stimulators and suppressor of the innate and adaptive immune system, on osteoimmunological modes of action of low radiation doses, on combination of radio(chemo)therapy with immunotherapies, on hyperthermia and immunophenotyping, as well as on translational clinical studies. He was WP leader of several EU funded projects and currently is key scientist and deputy head of a German research network dealing with the influence of exposure to low doses of radiation on the innate and adaptive immune system. He further heads a consortium funded by the Bayerische Forschungsstiftung on multiscale investigations of hyperthermia as additive treatment strategy for solid tumors. He is scientific PI auf more than 10 registered clinical trials and his research has been funded by the German Research Foundation (DFG), by the European Commission (FP6 and FP7), by the German Federal Ministry of Education and Research (BMBF), by the Doktor Robert Pfleger-Stiftung, by the Thomas Wildey Institut, and by the Bayerische Forschungsstiftung. Since 2020 he is co-speaker of the DFG-funded research training group GRK2599 “FAIR – Fine-tuners of the adaptive immune response". Furthermore, since 2020 he is Section Editor of Radiation Biology of Strahlentherapie und Onkologie (Journal of Radiation Oncology – Biology – Physics) and has been Associate and Academic Editor for Frontiers in Immunology/Oncology and for the International Journal for Molecular Sciences, respectively.